None
Quote | Can-Fite Biopharma Ltd Sponsored ADR (NYSE:CANF)
Last: | $2.42 |
---|---|
Change Percent: | 0.83% |
Open: | $2.39 |
Close: | $2.40 |
High: | $2.4799 |
Low: | $2.36 |
Volume: | 17,622 |
Last Trade Date Time: | 07/03/2024 03:00:00 am |
News | Can-Fite Biopharma Ltd Sponsored ADR (NYSE:CANF)
Liver cirrhosis treatment global market is estimated to reach $29.2 billion by 2030 Ramat Gan, Israel, July 01, 2024 (GLOBE NEWSWIRE) -- Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE:CFBI), a biotechnology company with a pipeline of proprietary small molecule drugs that addr...
The canine osteoarthritis market is projected to reach $3 billion by 2028 Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE: CFBI), a biotechnology company advancing a pipeline of proprietary small molecule drugs that address oncological and inflammatory diseases, today announced ...
Message Board Posts | Can-Fite Biopharma Ltd Sponsored ADR (NYSE:CANF)
Subject | By | Source | When |
---|---|---|---|
Can-Fite to Present at the Emerging Growth Conference | midastouch017 | investorshub | 07/07/2023 12:12:19 PM |
$CANF Price now last up | kindness | investorshub | 07/05/2023 12:30:23 PM |
$CANF MomentumIts gaining last up | midastouch017 | investorshub | 07/02/2023 3:49:17 AM |
$CANF Price gaining | JoEy D BuLL | investorshub | 07/01/2023 12:07:54 AM |
$CANF Price gaining last trade up | midastouch017 | investorshub | 06/29/2023 2:57:59 PM |
News, Short Squeeze, Breakout and More Instantly...
Can-Fite Biopharma Ltd Sponsored ADR Company Name:
CANF Stock Symbol:
NYSE Market:
Can-Fite Biopharma Ltd Sponsored ADR Website:
Liver cirrhosis treatment global market is estimated to reach $29.2 billion by 2030 Ramat Gan, Israel, July 01, 2024 (GLOBE NEWSWIRE) -- Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE:CFBI), a biotechnology company with a pipeline of proprietary small molecule drugs that addr...
The canine osteoarthritis market is projected to reach $3 billion by 2028 Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE: CFBI), a biotechnology company advancing a pipeline of proprietary small molecule drugs that address oncological and inflammatory diseases, today announced ...
Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE: CANF), a biotechnology company advancing a pipeline of proprietary small molecule drugs that address oncological and inflammatory diseases, today announces that company scientists came up with breakthrough findings showing that the anti-cance...